Last updated: November 7, 2023
Sponsor: National Cancer Center, Korea
Overall Status: Active - Not Recruiting
Phase
3
Condition
Stomach Cancer
Digestive System Neoplasms
Gastric Cancer
Treatment
Placebo
LAC triple therapy
Clinical Study ID
NCT01678027
NCCCTS04-103
Ages 40-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Sibling or offspring of patients with gastric adenocarcinoma confirmed by EGD andbiopsy
- Informed consent should be signed
Exclusion
Exclusion Criteria:
- Gastric cancer history
- Other malignancy within the past 5 years
- Hereditary cancer family member (HNPCC, FAP)
- Peptic ulcer history
- Peptic ulcer, esophageal cancer, gastric cancer case found at EGD
- H. pylori eradication treatment history
- Previous serious side effect to antibiotics
- Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renalfailure, cardiovascular diseases
- Pregnant or nursing women
- Psychiatric disorder that would preclude compliance, alcoholics
- Refuse informed consent
Study Design
Total Participants: 1838
Treatment Group(s): 2
Primary Treatment: Placebo
Phase: 3
Study Start date:
November 01, 2004
Estimated Completion Date:
December 31, 2035
Study Description
Connect with a study center
National Cancer Center, Korea
Goyang, Gyeonggi 10408
Korea, Republic ofSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.